Bharat Biotech International Limited
24
1
3
14
Key Highlights
Risk & Performance
Pipeline Risk Assessment
Pipeline Risk Assessment
Based on historical performance
Low Risk
Score: 25/100
0.0%
0 terminated/withdrawn out of 24 trials
100.0%
+13.5% vs industry average
50%
12 trials in Phase 3/4
7%
1 of 14 completed trials have results
Key Signals
Enrollment Performance
Analytics
Activity Timeline
Global Presence
Clinical Trials (24)
A Seamless Phase II/III, Observer-blind, to Evaluate Immunogenicity and Safety of Chikungunya Virus Vaccine in Healthy Subjects 12-65Years of Age.
Role: lead
Safety and Immunogenicity of a Mycobacterium Tuberculosis Vaccine MTBVAC in Healthy Indian Adults and Adolescents (BBV169/2024)
Role: lead
Tuberculosis Vaccine in Healthy Indian Adults
Role: lead
The Efficacy of Oral Rotavirus Vaccine 116E (ROTAVAC 5D) in Chilean Infants
Role: lead
The Efficacy of Three Doses of Live Attenuated, Oral Rotavirus Vaccine 116E
Role: collaborator
To Evaluate Safety of Oral Cholera Vaccine Hillchol® (BBV131)
Role: lead
BBV152/BBV154 Heterologus Prime-Boost Study
Role: lead
Phase 3 Study to Evaluate Immunogenicity and Safety of BBV154 Booster Dose
Role: lead
Phase III Study of BBV154 Intranasal Vaccine in Healthy Volunteers
Role: lead
COVAXIN in a Pediatric Cohort
Role: lead
Whole-Virion Inactivated SARS-CoV-2 Vaccine (BBV152) for COVID-19 in Healthy Volunteers
Role: lead
A Phase III Randomized, Modified Double-blind, Multi-centric, Comparative Study, to Evaluate the Non-inferiority of Immunogenicity and Safety of Hillchol® (BBV131)to Shanchol™ Along With Lot-to-lot Consistency of Hillchol®(BBV131).
Role: lead
Safety and Immunogenicity of an Intranasal SARS-CoV-2 Vaccine (BBV154) for COVID-19
Role: lead
To Determine the Safety and Efficacy of Liquid ROTAVAC 5C Vaccine Against Childhood Diarrhea Caused by Rotavirus
Role: lead
An Efficacy and Safety Clinical Trial of an Investigational COVID-19 Vaccine (BBV152) in Adult Volunteers
Role: lead
A Trial Using Double-Bolus THR-100 Versus Streptokinase
Role: lead
Dose Escalation Study to Evaluate Oral Rotavirus Vaccine 116E Live Attenuated in Healthy Infants 8 to 20 Weeks Old
Role: lead
Study of BBIL's ROTAVAC® and ROTAVAC 5CM Vaccines in Zambia
Role: collaborator
Clinical Trial to Evaluate the Immunogenicity of Chikungunya Vaccine
Role: lead
Evaluate Immunogenicity, Safety, and Reactogenicity of Rotavac in Healthy Infants in Vietnam
Role: lead